Results 241 to 250 of about 31,215 (290)

Management of sulfonylurea ingestions

Pediatric Emergency Care, 1999
In the majority of pediatric patients with an unintentional ingestion of a sulfonylurea, observation and, if necessary, intravenous glucose supplementation, are sufficient. However, with cases of persistent hypoglycemia or cases refractory to IV glucose supplementation, attempts to inhibit insulin secretion should be considered.
openaire   +2 more sources

Rational use of sulfonylureas

Postgraduate Medicine, 1992
The clinical use of sulfonylureas described in this article is both rational and effective for diabetic patients. Sulfonylureas are not used (1) in patients with insulin-dependent (type I) diabetes, because they are completely ineffective or (2) in patients with non-insulin-dependent (type II) diabetes who respond satisfactorily to diet, because they ...
openaire   +2 more sources

[Sulfonylurea].

Nihon rinsho. Japanese journal of clinical medicine, 2015
SU drug promotes insulin secretion by acting on pancreatic β cell. The hypoglycemic effect is the most powerful among oral diabetic drugs with high cost-effectiveness. Particularly for the Japanese with type 2 diabetes caused by a decrease in insulin secretion as a main pathological condition, it was widely used until the present since 1957 and largely
openaire   +1 more source

Clinical pharmacology of sulfonylureas

Metabolism, 1987
Sulfonylureas seem to have similar mechanisms of action, including an acceleration and increase of insulin secretion, an increase of the systemic availability of insulin, and probably indirectly, an increase of insulin action. Sulfonylureas may postpone the development of impaired glucose tolerance (IGT) to manifest non-insulin-dependent diabetes ...
openaire   +2 more sources

Sulfonylureas

2006
  +4 more sources

Broad-specific immunochromatography for simultaneous detection of various sulfonylureas in adulterated multi-herbal tea

Food Chemistry, 2022
Anastasios P Koidis, Xiangmei Li, Xing Shen   +2 more
exaly  

Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records

Lancet Diabetes and Endocrinology,the, 2023
Yan Xie, Benjamin Bowe, Hong Xian
exaly  

The role of sulfonylureas in the treatment of type 2 diabetes

Expert Opinion on Pharmacotherapy, 2022
Brian Tomlinson, Manson Fok, Paul Chan
exaly  

Sulfonylureas

Reactions Weekly, 1991
openaire   +1 more source

Recent Advances in the Synthesis of Sulfonylureas

European Journal of Organic Chemistry, 2021
Vinicio Zanirato
exaly